Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889873 | 0.86 | ADORA1 (0.56) | ADORA1ADORA2A | |
| SCHEMBL6889869 | 0.86 | ADORA1 (0.56) | ADORA1ADORA2A | |
| SCHEMBL15425805 | 0.80 | ADORA1 (0.70) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL4251031 | 0.80 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BEGFR | |
| SCHEMBL4251032 | 0.80 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BEGFR | |
| SCHEMBL4251034 | 0.80 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BEGFR | |
| SCHEMBL4496406 | 0.79 | ADORA1 (0.78) | ADORA1ADORA2AADORA3ADORA2BEGFR | |
| SCHEMBL15426758 | 0.78 | ADORA1 (0.77) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL15425807 | 0.76 | ADORA1 (0.81) | ADORA1ADORA2AADORA3ADORA2BEGFR | |
| SCHEMBL15426757 | 0.75 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| EP-2050751-A1 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2003048120-A2 | 2-ARYL PYRROLOGPYRIMIDINES FOR A1 AND A3 RECEPTORS | OSI PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | ADORA1 2/4885ADORA2A 3/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.